Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoCSR-Omics: Serplulimab + CAPOX and SCRT in Locally Advanced Rectal Cancer
NCT07898865Phase 2Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of serplulimab in rectal cancer (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Complete Response at 1 year. Started Oct 2025; status: recruiting.
02
Drugs
serplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07898865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07898865.